Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel cartilage repair therapy

11.04.2002


Diseases involving irremediable tissue damage of the musculoskeletal system account today for about 15% of hospital admissions in developed countries. With the ageing of the population, this is believed to gain significantly in importance in the coming years.



The majority of the disorders affecting the musculoskeletal system are the joint diseases, in particular osteoarthritis. The latter disease process is typically initiated and associated with defects of the articular cartilage and the underlying bone, causing pain as well as functional impairment. Early tissue repair resulting in the functional restoration of damaged joint surfaces is expected to prevent the development of osteoarthritis, and slow down the progression of the disease.

Different solutions and therapies are currently available for the local treatment of joint surface defects. Ranging from small-scaled arthroscopic debridement with microfracture or osteochondral grafting, to radical surgery involving total joint replacement by implantation of prosthesis. However, as the lifetime of joint prosthesis is limited, and with the ageing of the population, there is an increased need for more long lasting biological repair procedures.


Recent therapeutic approaches aim at repairing the articular cartilage by implantation of expanded cartilage cells. Cells used for the procedure are often autologous chondrocytes (i.e. a patient’s own cartilaginous cells), obtained from the patient`s involved joint via biopsy. Main difficulties with this technology include, amongst others, the so called “de-differentiation” of the cells which, during the in vitro expansion, loose their proper function i.e. the potential to form stable hyaline cartilage. The expanded cells instead can only make disorganized low quality fibro-cartilaginous tissue having different functional properties than the original articular cartilage covering the joints. Many existing therapeutic tissue regeneration methods therefore may lead to failure in mid- and long-term and, sometimes, may even aggravate the local damage.

TiGenix improves the Autologuous Chondrocyte Implantation procedure

The recently founded Belgian company TiGenix has been able to overcome this difficulty, unblocking herewith the way for successful and long-lasting tissue regeneration. Focusing on joint-surface defects and based on its own research, the company has been able to consistently grow the required hyaline-type cartilage in vivo. TiGenix has discovered specific molecular markers which are used to predict the ability of a cell population to form stable hyaline cartilage in vivo.

From these research findings, TiGenix has subsequently developed the cellular therapeutic product ChondroCelect®. ChondroCelect® is a proprietary technology using the patient`s own cells, resulting in a consistent and reproducible cell product, expected to improve the outcome of an autologous chondrocyte implantation procedure.
ChondroCelect® recently entered a prospective randomized clinical trial in 9 orthopedic centers in Belgium. The company actively prepares the extension of the trial to medical centers in other European countries. The commercial launch of ChondroCelect® is foreseen in 2004.

Therapies of next generation

The repair of chondral (cartilage) defects is the first application of TiGenix` research. The company has also identified specific markers that will enable the selection of adult multipotent precursor cells as the basis for next-generation tissue repair. The latter include therapeutic solutions for osteochondral (cartilage and underlying bone) defects and ultimately novel treatment options for osteoarthritis.

Who is TiGenix ?

TiGenix was founded in February 2000 as a spin-off of the University of Leuven (Belgium) by Frank Luyten, M.D., Ph.D., Professor at the Faculty of Medicine of the University of Leuven and Chairman of the Department of Rheumatology at the same university; and Ir. Gil Beyen, Partner at Arthur D. Little in Brussels and specialist in the healthcare sector.

TiGenix is a biomedical company with the mission of developing innovative products for successful repair and functional regeneration of damaged human tissue. The company aims at becoming one of the leading players in the field of musculoskeletal tissue engineering.

To do so, TiGenix is built on a multidisciplinary technology platform, combining expertise in cell and developmental biology, biomaterials and biosurgery. Various collaborations and strategic partnerships have been put in place to ensure the technological advancement and further developments of TiGenix, including with leading research centers, a bioinformatics company as well as Belgian and international experts as scientific advisors.

Currently Tigenix employs 20 people of which 11 are active in Research & Development. The new offices are located near the city of Leuven, while the company`s own GMP cell expansion facilities are located in the premises of the nearby Leuven University hospital center.

To date, TiGenix has been financed through seed capital, in a round led by Gemma Frisius Fund, and through technology grants from the Flemish government. To finance its further development and expansion strategy, the company is currently raising additional equity capital through a private placement.

Patrick Valkenberg | alphagalileo

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>